Last €2.42 EUR
Change Today -0.102 / -4.04%
Volume 409.4K
As of 1:39 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

paion ag (PA8) Snapshot

Open
€2.50
Previous Close
€2.53
Day High
€2.53
Day Low
€2.40
52 Week High
02/26/14 - €4.47
52 Week Low
08/7/13 - €0.51
Market Cap
119.6M
Average Volume 10 Days
463.9K
EPS TTM
--
Shares Outstanding
49.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PAION AG (PA8)

Related News

No related news articles were found.

paion ag (PA8) Related Businessweek News

No Related Businessweek News Found

paion ag (PA8) Details

PAION AG, together with its subsidiaries, operates as a biopharmaceutical company that develops and commercializes drug candidates for diseases or interventions. The company’s portfolio of drug candidates include Remimazolam, a short-acting general anaesthetic/sedative agent that is in Phase-III clinical trials for the treatment of anaesthesia and procedural sedation, as well as in Phase-II clinical trials for ICU sedation. Its drug candidates also comprise Solulin, a variant of the human protein thrombomodulin in Phase-I clinical trials to stabilize the initial fibrin clot to stop bleeding; PN 13, a thrombomodulin mutant in preclinical stage to treat haemophilia and hyperfibrinolysis; and GGF2, a glial growth factor 2 that has completed Phase-I clinical trials to stimulate the growth and differentiation of various cells, including glial cells to demyelinate diseases, such as multiple sclerosis, damage of the myelin sheath, and degeneration of nerve cells. The company was founded in 2000 and is headquartered in Aachen, Germany.

13 Employees
Last Reported Date: 05/7/14
Founded in 2000

paion ag (PA8) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €383.2K
Co-Founder, Chief Medical Officer and Member ...
Total Annual Compensation: €352.1K
Compensation as of Fiscal Year 2013.

paion ag (PA8) Key Developments

PAION AG Grants Licence to Remimazolam in Canada to Pendopharm

PAION AG and Pendopharm signed the final license agreement for Remimazolam. The agreement grants Pendopharm an exclusive licence for the development and commercialization in the territory of Canada. Under the licence agreement, PAION will be eligible to receive future milestone payments of CAD 5.7 million and significant double digit tiered royalties on net sales in Canada starting at 15%.

Paion and R-Pharma Extends Licensing Agreement

Paion and R-Pharma extended their licensing agreement. Under the extended agreement, R-Pharma has obtained rights to market Paion's remimazolam product in the Middle East and North Africa region. Under the terms of the agreement, Paion will receive EUR 1.5 million in upfront payments, EUR 5.5 million in milestone payments and 'low double digit' royalties. The development and marketing of the product in the MENA region will be managed by R-Pharma's Turkish subsidiary TR-Pharm.

Paion AG Presents at BIO International Convention, Jun-24-2014 02:30 PM

Paion AG Presents at BIO International Convention, Jun-24-2014 02:30 PM. Venue: San Diego Convention Center, San Diego, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PA8:GR €2.42 EUR -0.102

PA8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PA8.
View Industry Companies
 

Industry Analysis

PA8

Industry Average

Valuation PA8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.2x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAION AG, please visit www.paion.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.